The continual reassessment method provides a new approach for estimating the maximum tolerated dose in a phase I clinical trial. In this paper we investigate a potential stopping rule for this method. We indicate certain situations in which the finally chosen dose level can be predicted with certainty after having included a number of patients strictly less than the projected sample size. There is therefore a clear gain when the only purpose of the trial is to identify a target dose for future experimentation. When prediction with certainty is not possible, we can still estimate the probability that the current level will be the same as all subsequent recommended levels.
INTRODUCTION
The continual reassessment method developed by O'Quigley, Pepe & Fisher (1990) is a method for estimating the maximum tolerated dose in phase I clinical trials. In practice the notion of maximum tolerated dose translates into some targeted percentile from the unknown dose-toxicity curve. The basic features of the method, distinguishing it from stochastic approximation as investigated by Wu (1986) , are the use of a single parameter dose-toxicity working model 4i (x, a) and a limited range of m discrete doses x lt ...,x m .
For continuous doses, stochastic approximation is known to converge. It has been shown by that for a discrete range of doses the continual reassessment method, under certain conditions, converges to the maximum tolerated dose, x^.
As described in O'Quigley et al. (1990) and O'Quigley (1992) , one assumes the inclusion of n sequentially entered patients in the trial; i.e. before treating the jth patient (; > 1) the reactions, toxic or non-toxic, of all previous patients to their respective administered dose are known. The information obtained from the first j-l patients is used to provide an updated estimate of the parameter a. This information is used in turn to update the estimated probabilities of toxicity at each of the available doses and these estimates are then used to recommend the dose x(j)e {Xi,..., x m }, to be administered to the jth patient. At the end of the trial, the estimated maximum tolerated dose is given by the dose x(n +1) that would have been recommended to the (n + l)st patient were they to be included in the trial.
Such a sequential approach, interchanging successively the design aspects and the estimation problem, appears the most satisfactory way of addressing the ethical concerns of phase I studies. These considerations would seem to dictate that successive patients be treated at the best level, given the accumulated information. Motivated by ethical and economic concerns, experimenters frequently feel that phase I trials should be halted as early as possible in order to proceed with phase II studies. This is often the case in oncology where the usefulness of experimental treatments cannot be determined before the completion of lengthy phase II studies. Bearing this in mind, consider the following possible sequence of events occurring in the latter part of a phase I study with fixed sample size n. For some j < n one observes
In words, the same dose is maintained for the last n -j subjects; it is also the estimated x^. If this information were available to the experimenters immediately following the inclusion of patient j, they could decide that the goal of the study had been achieved. In the light of such information it njay seem appropriate to bring the phase I study to a close rather than include the remaining subjects. In fact, for certain fixed maximum sample size designs, a stage may be reached where no possible set of further outcomes will be capable of overturning the current recommendation.
More generally, although the set of future outcomes may not necessarily maintain the same dose with probability one, this probability may still be quite high. How high it is depends on a number of factors including the unknown probabilities generating the data as well as the chosen working model. Nevertheless, if this probability can be approximated with good accuracy, then it could lead naturally to the construction of a dynamic stopping rule.
More precisely, suppose one plans a phase I trial that includes n patients. For each j < n, we would like to be able to say something about the probability that the dose recommended to patient j + 1 will be the same dose as that recommended to all the remaining patients as well as the estimated x^-The goal of this paper is to introduce a procedure which enables the experimenter to predict all the possible outcomes of a continual reassessment method phase I trial. Using this procedure we can estimate the probability that there will be no change in levels for the remainder of the study. If this probability is equal to 1 then so is the estimate. As soon as this probability is not 1, it cannot be known exactly. However it can be estimated consistently. Our simulation results suggest that these estimates are reliable enough to be of real practical use.
A DYNAMIC STOPPING RULE
Let us briefly recall the usual notation for the continual reassessment method. The experimenter projects n patients and m doses in the trial. The observations during a trial are coded via two random variables, X, taking values x u ...,x m , denoting the dose level used for an experiment, and a binary response variable Y where 7=1 denotes a toxicity and 7 = 0 denotes no toxicity.
The method supposes a simple increasing dose toxicity function \ji(x, a) that is rich enough so that for each 9 e (0, 1) there exists a value a giving \j/{x, a) = 6. In particular With this set-up, the goal of the experiment is to find the dose XMT e{x 1 ,...,x m } such that is as close as possible to 6 0 , the targeted probability. In its original Bayesian formulation the method operates in the following way. One starts with a simple one-parameter working model for the probabilities of toxicities of the doses and an initial distribution for a having mean /i(0) such that
These initial values for the toxicities could reflect the experimenter's prior beliefs about the toxicities of the available doses. After observing the reactions of the first i patients, one is able to reassess these notions via the posterior distribution of a having mean denoted by n(i). Alternatively, with some slight modifications we can use a likelihood approach as in . In this context, one denotes by 3, the maximum likelihood estimator of the parameter a obtained after the inclusion of the first i patients. This is the notation we adopt for the remainder of this work. Thus, we have at the ith step new estimates of the dose toxicities, namely, The dose recommended to patient i + 1 is the dose x(i + 1) e {x lt ..., x m } that satisfies
A trial continues until all n patients have been included. The dose recommended as the estimated *MT f°r phase II trials is x{n + 1), the dose that would have been allocated to patient n + 1 were he to participate in the trial. Next, suppose that j patients have already been included in a trial and that we wish to know whether or not the inclusion of the remaining n -j patients is necessary. It seems reasonable to require that a stopping rule provide us with information about x(j + 2),...,x{n + l) once x(l),..., x(j + 1) and the reactions for the firstj patients are known. More precisely, for j < n, we are interested in the quantity where 1 if patient j experiences a toxicity, 0 otherwise.
In words, ^, n is the probability that x{j + 1) is the dose recommended to all remaining patients in the trial and is the final recommended dose at the end of the trial. Thus, to find & jiH one needs to determine all the possible outcomes of the trial based on the results known for the first j patients. The following algorithm does exactly that. We use the notation T} " to refer to the tree constructed with this algorithm. Each path in 7} " that starts at the root and ends at a leaf whose nodes all have the same label represents a trial where the recommended dose is unchanged between the (j + l)st and the (n + l)st patient. The probability of each such path is given by where R(j + l) = pr{y= l\X = x(j+ 1)} and r is the number of toxicities along the path. By exclusivity we can sum the probabilities of all such paths to obtain & iJt . Observe that this probability is completely determined by the true underlying probability of toxicity at the level x(j + 1). Using "AM./ + 1). ^j+i}. the current estimate of the toxicity of x{j + 1), we may estimate the probability of each path with 1), *,} Adding up these path estimates yields an estimate of & iJt .
To formalise this idea we need to introduce some additional notation. Let Wjj, denote the set of paths in 7} " that start at the root and end at a leaf and all of whose nodes have the same label. For c e ^n, let \c\ denote the number of toxicities encoded by c. With this set-up one haŝ
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By letting A r = \{ce < # J _ n :\c\ = r}\, we can rewrite (1) as follows:
Setting p = \j/{{j +1), Uj), we have the estimate
The algorithm is best illustrated with an example.
Example. We suppose n = 16 patients are to be included in the trial. Our simulation consists of observing the reactions for the first ; = 13 patients and then estimating & iJt .
In this illustration, we suppose the true toxicities of the six available doses are given by R t = 0-03, R 2 = 0-22, R 3 = 0-45, R 4 = 0-60, R 5 = 0-80, R 6 = 0-95. Additionally, we use the maximum likelihood approach with the dose-toxicity model
\j/(x t , a) = a?
and working model a t = 004, a 2 = 0-07, a 3 = 0-2, a 4 = 0-35, a 5 = 055, a 6 = 0-7. Table 1 indicates the initial sequence of events in the trial. In order for the likelihood method to work we must encounter heterogeneity in an initial sequence of responses. To initialise this simulation we follow the approach suggested in O'Quigley & , which is to allocate three patients at a time to increasing dose levels until heterogeneity is obtained. We now construct the tree 7i 3il6 of possible events that can occur in this trial after administering dose 2 to patient 14; see Fig. 1 . The label of each node represents the dose that would be recommended after the sequence of responses preceding that node in the tree. Thus, for example, we would recommend dose 2 to patient 15 regardless of whether or not patient 14 suffered a toxicity.
Using the estimate 3 13 = 064, we estimate the toxicity of dose 2 to be ^ = a^1 3 = 018. This estimate permits us to assign values to the paths of the tree which correspond to no change in dose level. Using Fig. 1 we can write # 13>16 = {000, 001,010,100} with A o = 1, A y = 3 and A 3 = 0. This enables us to use (3) to estimatê 13,16 = M1 -P) 3 + ^i(l -PfP = (082) 3 + 3(0-82) 2 (0-18) = 091.
It is interesting to note that the true value is obtained by substituting K(14) = R 2 = 0-22 in (2) 1. Deterministic outcome If all the nodes of the tree 7} >n are labelled with the same dose, then and 9 i>n are both equal to 1. In this situation, the algorithm gives a completely deterministic result: regardless of further outcomes for the given trial all remaining patients will be recommended the dose x(j + 1). Were we to continue beyond this point in the trial we would improve the precision with which we estimate the probability of toxicity at x(n + 1). Often however the essential objective of the phase I study is to determine the maximum tolerated dose with a small number of patients. In such cases it may be appropriate to terminate the inclusion of further patients since the objective has already been achieved. In the example of § 2, for instance, note that successive non-toxicities or successive toxicities for patients 14 and 15 will lead to the same recommendation for patient 17 regardless of the outcome for patient 16.
3-2. Statistical properties
The goal of this section is to show that, under certain conditions, & Un is a consistent estimate of &]_". To this end, we need to show that the method eventually settles on a level. Our stopping rule is then a way to detect such convergence as soon as possible via & in . In it is shown that the method settles to the correct level when the underlying realities satisfy some basic constraints. Here we show that in the presence of weaker conditions the method still converges almost surely to some level.
We begin by letting p i} be the frequency of allocation to level x ( among the first j subjects and by denning p i by p~ij-+Pi, in probability, where the limit is assumed to exist. The following conditions on the model i/^(x, a) and the realities R t are required. and thus, by Condition M2, a s belongs to the interval S. Next, 3, e S combined with (6) forces the solution, dj, of Ij(a) = 0 to belong to S almost surely and hence \aj -dj\-*O. Now, Ptj->Pi, in probability, yields that both a } and dj tend to the solution a* of (4). By Condition Rl, we have that for i 4= /i Therefore, for all ; sufficiently large, x{j + 1) = x*. The proof that ^(d, -a*) -> ^(0, a 2 ) in distribution where a 2 = {\p(x h , a*)} ~2R h (l -R*) follows directly from . 
1=0 r=0 Jo
For the worked example provided at the end of § 2 we find that E(P M ) ^ 0-91 and var(<#, J ^= 0-009.
DISCUSSION
Looking forward from a given point in a trial to the end of the trial and using its probabilistic structure in order to come to an early close has already been considered. The context is usually that of hypothesis testing and stochastic curtailment in which the probability of the final test being significant at some level and power can be estimated (Lan, Simon & Halperin, 1982) .
Calculation of 9 iJt will be useful in practice. When & 1<n = 1, a clear decision can be made. When &)j, < 1 this quantity can still be of use in a deciding whether or not to halt the study. In this situation more caution is required since the exact distribution of & i<n is unknown and can only be approximated asymptotically. Nevertheless the results of § 3 and our own practical experience suggest that the approximation works well for samples between 16 and 25. In practice, for the purpose of early termination, one would usually only be interested in large values of & iJt . In order to obtain further insight we carried out a large number of simulations where 0-85^^n<l. The true probabilities 9 in were generated uniformly according to the 12 situations described by in which we fixed n = 20 and ; = 16. The observed distribution of \& jn -& jn \ was encouraging. In particular, it is infrequent that \&j_ H -Pjj,\>0-l, and \9 itK -9 iJt \ < 0-05 nearly § of the time.
The main ideas presented here would apply to other sequential designs having convergence properties. For instance, when dealing with non-life-threatening diseases or transient toxicities it may be appropriate to reformulate the problem in a classical decision theoretic framework. In this context the designs could be driven by different criteria such as D-optimality or variance minimisation. Since there may be a connection between the continual reassessment method and bandit problems with a high rate of discount, an experimenter could also consider the possibility of intermediate designs (Berry & Eick, 1995) .
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